Charles River Laboratories International Inc

Find Ratings Reports
CRL : NYSE : Health Care
$101.2 up 1.3 | 1.3%
Today's Range: 100.2407 - 101.69
Avg. Daily Volume: 357300.0
06/28/17 - 4:02 PM ET

Financial Analysis


CHARLES RIVER LABS INTL INC's gross profit margin for the first quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. CHARLES RIVER LABS INTL INC has average liquidity. Currently, the Quick Ratio is 1.36 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.

During the same period, stockholders' equity ("net worth") has increased by 12.38% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY17 Q1 FY16
Net Sales ($mil)445.76354.87
EBITDA ($mil)103.6582.8
EBIT ($mil)71.2458.15
Net Income ($mil)46.7837.14


Balance Sheet Q1 FY17 Q1 FY16
Cash & Equiv. ($mil)135.93176.38
Total Assets ($mil)2697.082103.72
Total Debt ($mil)1197.37861.86
Equity ($mil)876.43779.82


Profitability Q1 FY17 Q1 FY16
Gross Profit Margin43.5944.95
EBITDA Margin23.2523.33
Operating Margin15.9816.38
Sales Turnover0.660.66
Return on Assets6.097.36
Return on Equity18.7219.98
Debt Q1 FY17 Q1 FY16
Current Ratio1.832.06
Debt/Capital0.580.53
Interest Expense6.984.21
Interest Coverage10.213.81


Share Data Q1 FY17 Q1 FY16
Shares outstanding (mil)47.6447.11
Div / share0.00.0
EPS0.970.78
Book value / share18.416.55
Institutional Own % n/a n/a
Avg Daily Volume353410.0416864.0

Valuation


BUY. This stock's P/E ratio indicates a significant discount compared to an average of 51.68 for the Life Sciences Tools & Services industry and a premium compared to the S&P 500 average of 25.75. For additional comparison, its price-to-book ratio of 5.46 indicates a significant premium versus the S&P 500 average of 3.09 and a discount versus the industry average of 6.82. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, CHARLES RIVER LABS INTL INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
CRL 29.45 Peers 51.68   CRL 16.21 Peers 31.52

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

CRL is trading at a significant discount to its peers.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

CRL is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
CRL 17.91 Peers 29.47   CRL 0.51 Peers 0.99

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

CRL is trading at a significant discount to its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

CRL trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
CRL 5.46 Peers 6.82   CRL 3.96 Peers 14.97

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

CRL is trading at a discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, CRL is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
CRL 2.70 Peers 22.56   CRL 26.79 Peers 10.20

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

CRL is trading at a significant discount to its industry on this measurement.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

CRL has a sales growth rate that significantly exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades